HNWAG
CHRS icon

High Net Worth Advisory Group’s Coherus Oncology CHRS Stock Holding History

High Net Worth Advisory Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$7K – 689
2022
Q2 		$7K Hold
1,000
– – ﹤0.01% 555
2022
Q1 		$13K Hold
1,000
– – ﹤0.01% 495
2021
Q4 		$16K Buy
+1,000
New +$17.5K 0.01% 490

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

High Net Worth Advisory Group's CHRS Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 1,000 shares — an estimated $7K sold.

High Net Worth Advisory Group first reported a position in CHRS in Q4 2021 and held it in 3 quarters. The position peaked at $16K in Q4 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Coherus Oncology shares in Q3 2022, an estimated $7K.
  • High Net Worth Advisory Group first reported a position in Coherus Oncology in Q4 2021 and held it in 3 quarters.
  • High Net Worth Advisory Group's Coherus Oncology position peaked at $16K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.